<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0020">
 <label>Table 3</label>
 <caption>
  <p>Preliminary efficacy of the maternal RSV F-protein nanoparticle vaccine (Novavax) against severe RSV infection in infants.</p>
 </caption>
 <alt-text id="al0025">Table 3</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Endpoints</th>
    <th>Per-protocol analysis</th>
    <th>Pre-specified expanded data analysis which includes data from hospitalization records</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Primary</td>
    <td/>
    <td/>
   </tr>
   <tr>
    <td>Medically significant RSV LRTI</td>
    <td>39% (97.5%CI, − 1% to 64%)</td>
    <td>41% (95%CI, 16% to 58%)</td>
   </tr>
   <tr>
    <td>Secondary</td>
    <td/>
    <td/>
   </tr>
   <tr>
    <td>RSV LRTI Hospitalization</td>
    <td>44% (95%CI, 20% to 62%)</td>
    <td>42% (95%CI, 17% to 59%)</td>
   </tr>
   <tr>
    <td>RSV LRTI with severe hypoxemia</td>
    <td>48% (95%CI, − 8% to 75%)</td>
    <td>60% (95%CI, 32% to 76%)</td>
   </tr>
  </tbody>
 </table>
 <attrib>Source: Novavax press release, available at 
  <ext-link ext-link-type="uri" xlink:href="http://ir.novavax.com/news-releases/news-release-details/novavax-announces-topline-results-phase-3-preparetm-trial#" id="ir0015" xmlns:xlink="http://www.w3.org/1999/xlink">http://ir.novavax.com/news-releases/news-release-details/novavax-announces-topline-results-phase-3-preparetm-trial#</ext-link>.
 </attrib>
</table-wrap>
